Pipeline Programs
CGT Companies Tracked
Manufacturing Facilities
The U.S. full-spectrum CBD market was valued at approximately USD 4.00 billion in 2025 and is projected to reach USD 15.49 billion by 2035, expanding at a 14.5% CAGR from 2026 to 2035. The market includes hemp-derived and marijuana-derived full-spectrum CBD products across oils and tinctures, gummies and edibles, topicals, capsules, beverages and other formulations. Key companies include Charlotte's Web, CV Sciences, cbdMD, Lazarus Naturals, Green Roads, CBDistillery, Medterra, Joy Organics, Cornbread Hemp and NuLeaf Naturals.
| Metric | 2025/2026 |
| Market size, 2025 | USD 4.00 Billion |
| Market size, 2026 | USD 4.58 Billion |
| Forecast, 2035 | USD 15.49 Billion |
| CAGR, 2026–2035 | 15% |
| Hemp-derived share, in 2025 | 78% |
| Oils & tinctures share | 31% |
| General wellness & personal care in 2025 | 34% |
| Retail stores in 2024 | 36% |
| E-commerce in 2025 | 32% |
U.S. full spectrum CBD refers to products consisting of a complete range of naturally occurring cannabinoids, terpenes, and flavonoids along with trace amounts of THC (up to 0.3% for hemp-derived products under federal law), which are derived from the hemp or cannabis plant used across the U.S. These full spectrum CBDs are present in different types of retail products, where CBD oils/tinctures, topical creams, and gummies are the most commonly used products. These products are used in the management of chronic pain, age-related conditions, anxiety, and neurodegenerative diseases.
As the market research analyst, I interpret that the infographic stat panel illustrates Charlotte's Web-Abacus Health acquisition metrics. At the acquisition announcement, the company reported the combined F/D/M retail channel share of 34.7% and more than 21,000 combined retail doors following the merger. This acquisition was completed on June 11, 2020, which resulted in the addition of Abacus brands like CBD MEDIC, CBD CLINIC, and Harmony Hemp to Charlotte's Web.
Key Insight:
A cross-selling opportunity was created, supporting Charlotte's Web's current “Very Strong” topical-category rating, through this acquisition, which combined Charlotte's Web's ingestible CBD strength with Abacus's OTC topical and 16,500-practitioner distribution network, which was almost impossible to achieve independently by either company.
The given infographic stat panel covers BAT–Charlotte's Web 2026 recapitalization metrics. On March 30, 2026, the transaction was announced where C$75.3 million in convertible debenture plus accrued interest was converted to equity, along with the addition of $10 million in new equity investment. Moreover, new shares expected to be issued are approximately 110 million.
Key Insight:
The conversion of debt to equity, along with BAT's willingness to add $10 million in fresh capital, resulted in strengthening strategic confidence in the company's long-term hemp-wellness positioning.
Source: StockTitan, “BAT boosts stake as Charlotte's Web (CWBHF) outlines major share issuance and CBD growth,” March 2026.
According to the analysis conducted by Aman, the timeline infographic highlights Charlotte's Web's MLB partnership lifecycle from 2022 to 2025. On October 11, 2022, the MLB Promotional Rights Agreement was signed between the companies, while on May 13, 2025, the termination letter of the agreement was signed. This resulted in the termination of the " Official CBD of MLB " designation, with $18 million in remaining rights fee MLB agreed to waive.
Key Insight:
The mutual agreement to end the deal and waive the remaining $18 million obligation between both companies reflects that this partnership is no longer part of the active marketing strategy of Charlotte's Web.
Source: StockTitan, “BAT boosts stake as Charlotte's Web (CWBHF) outlines major share issuance and CBD growth,” March 2026 (citing the May 13, 2025 termination letter agreement).
Based on our research, the horizontal bar chart compares three public CBD companies' FY2025 revenue. Charlotte's Web achieved the highest FY2025 revenue of $49.9 million, which was followed by cbdMD with $19.2 million in FY2025 revenue, and $13.8 million in FY2025 revenue of CV Sciences.
Key Insight:
The revenue covered by the companies falls below $100 million in annual revenue achieved by any of the largest publicly reporting full-spectrum CBD companies, which indicates that this category remains much smaller relative to adjacent consumer wellness and pharmaceutical markets.
Source: Charlotte's Web Holdings, Inc., SEC Form 10-K, FY2025; CV Sciences, Inc., Fiscal Year-End 2025 Financial Results, March 26, 2026; Towards Healthcare (cbdMD).
As per the information gathered by Aman, the bar chart encompasses CV Sciences' annual revenue for FY2024 vs. FY2025. The product's net sales in FY2024 were reported to be $15.7 million, and FY2025 was noted to be $13.8 million. The gross margin for FY2024 and FY2025 was recorded to be 45.6% and 49.0%, respectively. The FY2024 revenue for operating expenses contributed $9.4 million, while FY2025 accounted for $7.7 million.
Key Insight:
The product's net sales demonstrated a 12.1% revenue decline along with a 17.2% reduction in operating expenses, which reflects that the company’s net loss was reduced from $2.4 million to $958,000 year-over-year as its cost-cutting overtook sales contraction.
Source: CV Sciences, Inc., “Reports Fiscal Year-End 2025 Financial Results,” March 26, 2026.
The above-mentioned infographic stat panel covers Charlotte's Web's patent and hemp-cultivar portfolio metrics. The company consists of a total of 11 U.S. patents and 5 patented proprietary hemp cultivars. It is also focusing on cannabinoid processing patents, including whole-plant extraction and modification systems, as well as delivery-technology patents, that is, transdermal CBD topical pain-relief formulations.
Key Insight:
Proprietary hemp cultivar patents offer a genetics-level competitive moat to Charlotte's Web, which is substantially harder for competitors to replicate compared to any patented formulation or processing methods.
Source: Towards Healthcare, citing Charlotte's Web investor-relations patent disclosures.
According to the survey conducted, the ecosystem infographic illustrates Charlotte's Web's three-part diversification strategy. The company is focusing on functional mushrooms to enhance adjacent wellness category expansion beyond hemp-derived products, low-dose THC gummies to launch a new cannabinoid-adjacent product category, and DeFloria (botanical drug development), which is an FDA Phase 2-cleared subsidiary pursuing a formal drug-development pathway.
Key Insight:
The growing interest of the company in functional mushrooms, THC gummies, and formal FDA drug development is expanding its diversified hedge across adjacent consumer categories and an entirely different regulatory pathway instead of a single diversified strategy.
Source: StockTitan, “BAT boosts stake as Charlotte's Web (CWBHF) outlines major share issuance and CBD growth,” March 2026.
As the market research analyst, I interpret that the infographic stat panel covers DeFloria FDA Phase 2 clearance metrics. Charlotte's Web's most recent annual (10-K) filing disclosed that its botanical drug development arm, DeFloria, which is a botanical drug, distinct from the dietary-supplement route, is in a Phase 2 FDA clinical trial.
Key Insight:
Charlotte's Web will be positioned alongside dedicated pharmaceutical cannabinoid developers after DeFloria's Phase 2 clearance, exposing it to formal pharmaceutical drug development and introducing a fundamentally different risk/reward profile than its consumer-wellness CBD business.
Source: StockTitan, “BAT boosts stake as Charlotte's Web (CWBHF) outlines major share issuance and CBD growth,” March 2026.
The given ecosystem infographic focuses on the four strategic groups within the U.S. full-spectrum CBD competitive field. Charlotte's Web led the industry as the market leader, while Lazarus Naturals, CBDistillery, and Green Roads are the established challengers. Furthermore, CV Sciences/+PlusCBD, Medterra, and Joy Organics are the renowned science-led/premium players, whereas Cornbread Hemp and NuLeaf Naturals contribute as the fast-growing specialists.
Key Insight:
The presence of only one identified market leader that is Charlotte's Web, makes the market's competitive structure resemble a single-leader-plus-fragmented-field instead of two-company rivalries.
Source: Towards Healthcare, cross-referenced against publicly identified competitor lists for full-spectrum CBD market coverage.
According to the survey conducted by Aman, the infographic stat-panel encompasses data availability and category fragmentation metrics. A total of 3.07% share of the broader CBD category was reported by Charlotte's Web, while each of Green Roads, Lazarus Naturals, NuLeaf Naturals, and CV Sciences contributed less than 0.3% share each. Additionally, 10 companies were identified as leading full-spectrum competitors, which were based on qualitative competitive positioning, and not on invented percentages.
Key Insight:
With the market leader holding just 3.07% of the broader CBD category suggests that it is one of the most fragmented markets, with precise company-level share claims for the full-spectrum-only and less reliable sub-segment than the broader category.
Source: Towards Healthcare, correctly distinguishing broader CBD category share data from unavailable full-spectrum-specific figures.
Based on our research, the horizontal list chart reflects Charlotte's Web ratings across six competitive benchmarks. Charlotte's benchmarks like Brand Strength, Full-Spectrum Portfolio, Product Innovation, Distribution, and Scientific Positioning were rated ‘Very Strong,’ while only one benchmark that is DTC Strength, was rated ‘Strong’.
Key Insight:
The uniform top-tier ratings, verified patent, and recent BAT capital infusion with verified evidence instead of qualitative assessment alone altogether contribute to Charlotte's Web's “Market Leader” competitive designation.
Source: Towards Healthcare.
The above-mentioned infographic stat panel covers CV Sciences' retail distribution footprint metrics. In 2024, more than 2,500 brick-and-mortar stores were reported to carry CV Sciences which were distributed through online, distributor, and retail channels. Moreover, it introduced +PlusCBD as its flagship brand, which was supported by clinical research, whereas FY2025 revenue of $13.8 million was responsible for expanding this footprint.
Key Insight:
With the $13.8 million in revenue across more than 2,500 physical retail doors, CV Sciences contributes to a modest average revenue contribution per store, highlighting that its sales density is not yet translated compared to the larger competitors like Charlotte's Web.
Source: Towards Healthcare, citing CV Sciences company disclosures.
As per the analysis conducted, the horizontal bar chart represents competitive intensity ratings between Charlotte's Web and key rivals. Charlotte's Web’s competitive intensity with Cornbread Hemp and +PlusCBD is rated ‘Very High’, while it is rated ‘High' with companies like cbdMD, Green Roads, CBDistillery, and Lazarus Naturals.
Key Insight:
Despite a comparatively smaller distribution footprint, Cornbread Hemp was rated “Very High” competitive intensity, indicating that the competitive pressure on Charlotte's Web is driven by premium full-spectrum positioning.
Source: Towards Healthcare.
Based on the information gathered, the infographic stat-panel encompasses revenue scale comparison across public CBD filers. The FY2025 revenue of Charlotte's Web, cbdMD, and CV Sciences was noted to be $49.9 million, $19.2 million, and $13.8 million, respectively. This indicated a 3.6x revenue gap between the largest and smallest public filer.
Key Insight:
The revenue gap between the three companies was recorded to be 3.6x, which highlighted that not all ten companies disclosed their revenue data, implying that their revenue gap is likely to be far wider.
Source: Charlotte's Web Holdings, Inc., SEC Form 10-K, FY2025; CV Sciences, Inc., Fiscal Year-End 2025 Financial Results, March 2026; Towards Healthcare (cbdMD).
As the market research analyst, I interpret that the synthesis infographic illustrates three structural forces shaping the U.S. full-spectrum CBD competition. The first force is capital consolidation, highlighting BAT's $85M+ 2026 investment concentrating financial resources around the market leader. Second is retail fragmentation, indicating that even leading brands hold single-digit shares of the broader, highly fragmented CBD category. Third is diversification beyond CBD, covering Charlotte's Web pursuing mushrooms, THC gummies, and FDA drug development, hedging category risk.
Key Insight:
Charlotte's Web is expected to define the competitive benchmark with its strategic direction over the next several years, which is anticipated to receive a response from the fragmented ten-company field, as it is the recipient of major new outside capital (BAT) and is aggressively diversifying beyond core CBD business.
|
Indicator
|
Value
|
Source
|
|
Combined FY2025 revenue, 3 public CBD companies
|
$82.9 million
|
SEC filings; company competitive intelligence data
|
|
Charlotte's Web FY2025 revenue
|
$49.9 million
|
Charlotte's Web SEC Form 10-K, FY2025
|
|
BAT 2026 recapitalization commitment to Charlotte's Web
|
$85 million+ (C$75.3M debenture conversion + $10M equity)
|
StockTitan, March 2026
|
|
Charlotte's Web patents/proprietary hemp cultivars
|
11 patents/5 cultivars
|
Towards Healthcare
|
|
Charlotte's Web reported share of broader CBD category
|
3.07%
|
Towards Healthcare
|
|
CV Sciences retail store footprint, 2024
|
2,500+ physical stores
|
Towards Healthcare
|
The table represents revenues, recapitalization commitment patents, shares, and retail store footprints. The combined FY2025 revenue of 3 public CBD companies was noted to be $82.9 million. Charlotte's Web FY2025 revenue contributed $49.9 million, while its BAT 2026 recapitalization commitment included over $85 million, with C$75.3M debenture conversion and $10M equity. The company also revealed that it has 11 patents/5 hemp cultivars, and it also held a 3.07% share of the broader CBD category. In 2024, CV Sciences' retail store footprint contributed to over 2,500 physical stores.
This section covers four segmentation dimensions such as Source, Product Type, Application, and Distribution Channel, along with market-share, CAGR percentages, and real, verified data points.
The report covers a wide range of hemp-derived full-spectrum CBD companies like Charlotte's Web, CV Sciences, and cbdMD, where identification of hemp-derived CBD contributes as the dominant source category. Moreover, no verifiable marijuana-derived full-spectrum CBD company-level data was covered in the report, which highlights a significant gap instead of filling it with an estimate.
The product portfolio benchmark of Charlotte's Web was rated “Very Strong” across oils/tinctures, gummies, topicals, and pet CBD simultaneously, where this ingestibles-focused company gained traction with the acquisition of Abacus Health's topical brands in 2020, which added dedicated topical and practitioner-channel capability.
| Strategic Group | Recent Progression | Source |
| Market Leader (Charlotte's Web) |
|
SEC filings; StockTitan, 2026 |
| Science-Led Players (CV Sciences) |
|
CV Sciences fiscal year-end results, 2026 |
| Fast-Growing Specialists (Cornbread Hemp) | Rated 'Very High' competitive intensity against Charlotte's Web despite smaller scale | Towards Healthcare |
The table highlights different types of strategic groups and their recent progressions. Charlotte's Web is the market leader, which in 2026 announced FY2025 revenue of $49.9M, 11 patents/5 cultivars, and more than $85M in new BAT capital. CV Sciences held the science-led player position with over 2,500 retail stores in 2024 and $13.8M in FY2025 revenue. Additionally, Cornbread Hemp is recognized as the fast-growing specialist, as its competitive intensity was rated ‘Very High’ against Charlotte’s Web, irrespective of its smaller scale.
On March 26, 2026, fiscal year-end 2025 financial revenue of $13.8 million, which resulted in a decline of 12.1% from $15.7 million in 2024, along with an improved gross margin of 49.0% was announced by CV Sciences.
Source: CV Sciences, Inc., press release, March 26, 2026
On March 30, 2026, to convert a C$75.3 million convertible debenture plus accrued interest into equity with a concurrent $10 million private equity placement, a transaction with British American Tobacco (BAT) was announced by Charlotte's Web.
Source: StockTitan, March 2026
On May 13, 2025, to terminate the promotional rights deal, along with MLB relinquishing the remaining $18 million aggregate rights fee, which would have been due over the original term, a letter of agreement was signed between Charlotte's Web and MLB.
Source: StockTitan, March 2026
On October 11, 2022, an exclusive Promotional Rights Agreement was announced between Charlotte's Web and Major League Baseball, which made Charlotte's Web the “Official CBD of MLB.”
Source: Charlotte's Web SEC Form 10-K, FY2025
On June 11, 2020, the acquisition of Abacus Health Products by Charlotte's Web introduced CBD MEDIC, Harmony Hemp brands, and CBD CLINIC, promoting the largest vertically integrated hemp-derived CBD business of the company across the U.S.
Source: PR Newswire; Benzinga, 2020
It is the market leader with an $85M+ BAT recapitalization in 2026, 11 patents/5 hemp cultivars, and $49.9M FY2025 revenue, and it also reported the end of its partnership with MLB in 2025.
It is a strategic investor that converted a C$75.3M debenture to equity plus a $10M new investment in Charlotte's Web in March 2026.
It is a science-led specialist, with $13.8M FY2025 revenue, a flagship brand along with +PlusCBD, and more than 2,500 retail stores.
It is an established player operating Paw CBD and the ATRx Labs functional mushroom brand, and contributed to approximately $19.2M in FY2025 revenue.
It holds the position of an established challenger, which achieved a 'Very Strong' rating across its full-spectrum portfolio and DTC strength.
It is recognized as an established challenger with a 'Very Strong' rating in DTC strength and brand recognition.
It occupies the position of an established challenger, rated 'Very Strong' across brand recognition and gummies/edibles positioning.
It is a well-known premium challenger, rated 'Very Strong' in product innovation and topicals.
It holds the position of a fast-growing specialist, which was rated 'Very High' competitive intensity against Charlotte's Web despite its smaller scale.
It is a diversified cannabis player, where its CBD-only revenue was not disclosed within the broader cannabis business.
Aditi is a pharmaceutical research expert with strong experience in CBD products, functional mushrooms, and BAT's capital infusion markets. She conducted detailed market research, analyzed company data, clinical trends, and industry developments. Based on her comprehensive analysis, the following strategic key takeaways highlight the most important market insights and opportunities.
For Service Providers & CDMOs
For Pharma Companies
For Investors & Corporate Strategy Teams
Based on my assessment, the market is expanding rapidly due to increasing advancements in full spectrum CBD formulations and patents. The growth in low-dose THC gummies and other botanical drugs are also increasing their adoption rates. I also anticipate that the new collaboration among the major companies will accelerate their innovations. I also see strong growth in distribution channels and applications, which will create new market opportunities.
Payal Rabde led the primary market research, developed the methodology, analyzed trends, segmentation, competition, forecasts, and strategic opportunities, forming the report's analytical foundation.
Aman was responsible for collecting and validating clinical trial data, research publications, company information, partnerships, and other quantitative datasets, strengthening evidence-based analysis and market estimations.
Aditi reviewed the complete research document, performed quality checks, validated findings, refined content, corrected inconsistencies, and finalized the report, ensuring accuracy, clarity, credibility, and publication-ready quality.
By Source
By Product Type
By Application
By Distribution Channel
Principal Consultant
Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.
Learn more about Payal Rabde
Reviewed By
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.
Learn more about Aditi Shivarkar
